Table 1.

Number of Probes That Were Differentially Expressed in the Treated Groups Compared with Untreated Group

	Significance	p < 0.05	p < 0.05	p < 0.01
Group/group	Fold change	>1.5 or <0.67	1–1.5 or 0.67–1	>4 or <0.25	Total
B/A	Upregulation	180	87	3	270
	Downregulation	135	127	0	262
C/A	Upregulation	146	86	2	234
	Downregulation	114	87	0	201
D/A	Upregulation	853	325	92	1270
	Downregulation	864	421	1	1286
E/A	Upregulation	285	93	17	395
	Downregulation	188	131	0	319

Treatment groups are as follows. Group A = untreated; B = ¹¹¹In-trastuzumab (230 kBq); C = trastuzumab (approximately equal amount of antibody to group B); D = ¹¹¹In-trastuzumab-NLS-L (230 kBq); E = trastuzumab-NLS-L (approximately equal amount of antibody to group B). n = 3, each group.

NLS, nuclear localizing signal.